Biologics, like monoclonal antibodies and viral vectors, make up rapidly growing classes of drugs. They are also critical research tools and essential for the development of many new diagnostics.
While chromatography has been a mainstay of small molecules, these larger, bulky biologics require a new approach to downstream manufacturing. Isolere Bio was founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs.
We are currently focused on developing this technology for the manufacturing of antibodies and adeno-associated virus (AAV). We are working to develop a low-cost, high throughput, and scalable purification platform and are actively seeking research collaborators in development and validation.
Our product is made entirely recombinantly in E. coli and has no synthetic scaffold. This eliminates the cost of the solid support and chemical conjugation.
Our process scales linearly, providing a seamless transition from bench to industry scale production.
EASE OF USE
Our technology requires a simple tangential flow filtration (TFF) setup rather than complex chromatography equipment.
From high throughput 96-well plates, to all-in-one kits, to bulk reagent, our technology can be tailored to suit your needs.
Complete an entire round of purification with TFF in under 30 minutes! High flux will eliminate the capture step bottleneck and permeate control enables seamless development of a continuous downstream processes.
Our reagent binds and elutes the target in solution, eliminating the mass transfer constraints of traditional packed bed chromatography
Chromatography-free solutions for the purification of biological therapeutics such as monoclonal antibodies and viral gene delivery vectors.
Isolere welcomes Melissa Callander to the R&D team! Although their internships were delayed due to COVID, Isolere is also thrilled to welcome Nikki Votaw and Cameron Dyer.
Isolere receives an NSF supplement to apply its technology to adenovirus, a viral vector selected by several programs for COVID vaccine development.
Isolere begins working on IP strategy with Mike Tuscan and Erin Foley at Cooley, LLC. Isolere begins consulting with TFF expert, John Rozembersky.
THE ISOTAG TECHNOLOGY
This process is highly platform-able! Contact us to discuss custom reagent development to your therapeutic of interest. By replacing the antibody-binding domain with a different capture domain at the gene level, this versatile technology can be applied to other biotherapeutics.
FOUNDER & CHAIRMAN OF THE BOARD
Michael Dzuricky, PhD
CHIEF SCIENTIFIC OFFICER
Ashutosh Chilkoti, PhD
FOUNDER & CHIEF SCIENTIFIC ADVISOR
Kelli Luginbuhl, PhD
FOUNDER & CHIEF EXECUTIVE OFFICER
Isolere is hiring!
We are looking to fill several key positions:
Director of Nucleic Acids R&D Program - lead the application of our technology to mRNA (read more)
Director of Viral Vector R&D Program - lead the application of our technology to viral vectors, including lentivirus, retrovirus, adenovirus, and others (read more)
Director of Downstream Processing - take on a key role in helping us to develop robust, scalable, and platform process solutions for diverse biologics (read more)
Director of Reagent Discovery Program - help build an innovative phage display program for rapidly and robustly identifying high performance affinity reagents (read more)
Executive Assistant/Lab Manager - Assist company executives with scheduling, accounting, lab/office daily operations, and overall company organization (read more)